Functional studies demonstrated that deletion of Trem2 altered amyloid pathology in opposite directions depending on the stage of the disease (20–23), but overexpression of TREM2 reduced the pathology in transgenic mouse models of amyloidosis (24). The gene discussed is TREM2; the disease is amyloidosis.